Clinical studies have shown that increased bioavailable IGF-1 levels in serum of pancreatic cancer patients (relative to controls) are associated with accelerated pancreatic cancer death [47], [48]. This evidence concerns the gene IGF1 and familial pancreatic carcinoma.